Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

6P - Clinical and molecular characteristics in non-small cell lung cancer patients with alteration in PIK3 pathway.


24 Mar 2021


e-Poster Display Session


Yolanda Lage


Journal of Thoracic Oncology (2021) 16 (suppl_4): S699-S703.


Y. Lage1, P. Alvarez Ballesteros1, M.E. Olmedo García1, A. Gómez Rueda2, E. Corral de la Fuente1, J. Torres Jimenez1, E.M. Vida Navas3, J.J. Soto Castillo4, M. Lario1, A. Benito Berlinches1, A. Santón1, P. Garrido Lopez1

Author affiliations

  • 1 Hospital Universitario Ramon y Cajal, 28031 - Madrid/ES
  • 2 Hospital Universitario Ramon y Cajal, 13002 - Madrid/ES
  • 3 Medical Oncology, Hospital Universitario Ramon y Cajal, 28031 - Madrid/ES
  • 4 Hospital Universitario Ramon y Cajal, Madrid/ES

Abstract 6P


Currently non-small cell lung cancer (NSCLC) is a tumor with a broad spectrum of targeted therapies already available or in clinical trials. Molecular characterization of the tumor using next generation sequencing (NGS) technology has become a key tool for the molecular profiling of NSCLC, facilitating treatment decisions. The phosphoinositide-3-kinase (PI3 K) signaling pathway has a critical role in both tumorigenesis and the progression of disease and it represents an attractive target for novel anticancer therapies in NSCLC.


We performed a retrospective study of patients with NSCLC treated in Hospital Universitario Ramón y Cajal, with alterations in PIK3 pathway identified by NGS. Clinical characteristics and concurrent mutations were described.


1745 patients with lung carcinoma were treated in our institution between 2011 to 2020. We analyzed 479 patients with NSCLC who underwent NGS and 61 patients (12.7%) were identified with alteration in PIK3 pathway (tissue NGS in 43 and blood-based NGS in 19 patients). 57.3% of patients were diagnosed at IV stage. Most of them were men (67%) with smoking history (13% non-smokers). The most common histological types were adenocarcinoma (42%) and squamous cell carcinoma (36%). 27% of tumors were PD-L1 negative and 25 patients had determination of tumor mutational burden (>10 mut/Mb in 52%). PI3-kinase catalytic subunit alpha (PIK3CA) was the more common molecular finding (77% of patients): mutations exon 9 and 20 (82.5%), amplification (13.7%) and both (3.4%). We also found the presence of mutations of PTEN (tumor suppressor that negatively regulates the PIK3/AKT/mTOR pathway) in 6.5% and TP 53 in 59% of patients. Other mutations were detected in 27 patients (44.2%): EGFR (8%), KRAS (8,1%), ALK rearrangement (3.2%), BRAF (1.6%), MET (3.2%), FGFR (6.5%), CDKs (22.9%).


Our cohort shows that alteration in PI3 K pathway is more frequent in men with smoking history NSCLC patients and is not mutually exclusive to other mutations, that remark the relationship between pathways. Clinical trials are needed to predict the potential clinical benefit from the use of PI3 K pathway inhibitors.

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings